These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 14845363)

  • 21. Bacteriological results of treatment of lepromatous cases with diaminodiphenyl sulfone by mouth for periods up to five years.
    ROY AT
    Int J Lepr; 1956; 24(1):45-50. PubMed ID: 13366482
    [No Abstract]   [Full Text] [Related]  

  • 22. T cell responses to fractionated Mycobacterium leprae antigens in leprosy. The lepromatous nonresponder defect can be overcome in vitro by stimulation with fractionated M. leprae components.
    Ottenhoff TH; Converse PJ; Gebre N; Wondimu A; Ehrenberg JP; Kiessling R
    Eur J Immunol; 1989 Apr; 19(4):707-13. PubMed ID: 2659369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sulfone treatment of leprosy; the fate of succinyl-diamino-diphenyl-sulfone, a monosubstituted sulfone, in the body; mode of action].
    FLOCH H; LECUILLER A; DESTOMBES P
    Bull Soc Pathol Exot Filiales; 1951; 44(3-4):161-4. PubMed ID: 14839461
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of lepromatous leprosy by a combination of DDS and sarsaparilla (Smilax ornata).
    ROLLIER R
    Int J Lepr; 1959; 27():328-40. PubMed ID: 14438529
    [No Abstract]   [Full Text] [Related]  

  • 25. [General standards for sulfone therapy in leprosy; general concept; sulfones, composition and daily management; Minas Gerais sulfone factory; products already manufactured].
    MARIANO J
    Arq Min Leprol; 1951 Oct; 11(4):202-10. PubMed ID: 14924989
    [No Abstract]   [Full Text] [Related]  

  • 26. [Lepromatous patients during sulfone therapy. 1. Bacterioscopic reactivations. 2. Duration of therapy before obtaining negative test results].
    QUAGLIATO R; BERQUO E; LESER W
    Rev Bras Leprol; 1961 Mar; 29():19-30. PubMed ID: 13738624
    [No Abstract]   [Full Text] [Related]  

  • 27. Cured tuberculoid patients have a greater life expectancy than cured lepromatous patients in Japan.
    Goto M; Kitajima S; Nomoto M; Taki C; Yonezawa S; Imaizumi M
    Int J Lepr Other Mycobact Dis; 2003 Jun; 71(2):106-12. PubMed ID: 12914133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Note on some cases of leprosy (lepromatous type) treated with sulfones (diasone and sulfetrone)].
    GILLET J
    Ann Soc Belg Med Trop (1920); 1950 Sep; 30(3):441-7. PubMed ID: 14811222
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapeutic action of sulfone and sulfone compounds in leprosy].
    FLOCH H; RIST N
    Rev Bras Leprol; 1950 Sep; 18(3):111-6. PubMed ID: 14808751
    [No Abstract]   [Full Text] [Related]  

  • 30. ICONOGRAPHIA DERMATOLOGICA. 11. SUBCUTANEOUS "BORDERLINE NODULES" IN LEPROMATOUS LEPROSY.
    OGAWA J; KANETSUNA F; TODA E; NISHIURA M
    Hifuka Kiyo; 1963 Jan; 58():1-2. PubMed ID: 14045185
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of leprosy, particularly the tuberculoid form, with streptomycin, alone and with sulfones].
    RAMOS E SILVA J; PERYASSU D
    Bras Med; 1954; 68(32-52):439-50. PubMed ID: 14363492
    [No Abstract]   [Full Text] [Related]  

  • 32. Ocular complications in incident relapsed borderline lepromatous and lepromatous leprosy patients in south India.
    Daniel E; Koshy S; Joseph GA; Rao PS
    Indian J Ophthalmol; 2003 Jun; 51(2):155-9. PubMed ID: 12831146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacteriological status (point prevalence) of lepromatous outpatients under sulfone treatment.
    Quagliato R; Bechelli LM; Almeida JO; Araujo Arantes MA
    Bull World Health Organ; 1975; 52(1):57-62. PubMed ID: 764995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mannan-binding lectin plasma levels in leprosy: deficiency confers protection against the lepromatous but not the tuberculoid forms.
    Dornelles LN; Pereira-Ferrari L; Messias-Reason I
    Clin Exp Immunol; 2006 Sep; 145(3):463-8. PubMed ID: 16907914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of a monosubstituted sulfone (succinyl-diamino-diphenyl-sulfone or 1500 F in the treatment of leprosy].
    FLOCH H; DESTOMBES P
    Cah Med Union Fr; 1950 Nov; 5(44):711-7. PubMed ID: 14801712
    [No Abstract]   [Full Text] [Related]  

  • 36. Renal involvement in leprosy.
    Chopra NK; Lakhani JD; Pande RS; Modi KB; Pasle RK
    J Assoc Physicians India; 1991 Feb; 39(2):165-7. PubMed ID: 1885476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of circulating IgG subclasses against lipoarabinomannan in the leprosy spectrum and reactions.
    Beuria MK; Mohanty KK; Katoch K; Sengupta U
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):422-8. PubMed ID: 10700917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of leprosy treated by combined use of equal weights of two new di-substituted sulfones: diphenyl sulfone 4, 4'-bis (azo-para-isopropyl-metacresol) and its silver salts].
    TZANCK A; BASSET A; SALOMON L
    Bull Mem Soc Med Hop Paris; 1952 Jun 20-27; 68(22-23):749-52. PubMed ID: 12978850
    [No Abstract]   [Full Text] [Related]  

  • 39. Sulfone therapy in leprosy; a three year study.
    SLOAN NR; CHUNG-HOON EK; GODFREY-HORAN ME; HEDGCOCK GH
    Hawaii Med J; 1950; 9(5):301-4. PubMed ID: 15421588
    [No Abstract]   [Full Text] [Related]  

  • 40. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.